GlassScriptPhysician profile
Amir Najafi
NPI 1992064950
$770.67
in general payments reported to CMS, 2019-2025
15 companies · $20.90 in 2025
The $20.90 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.89 · 2020: $13.40 · 2021: $29.84 · 2022: $350 · 2023: $250 · 2024: $78.61 · 2025: $20.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.00 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $90.94 | 2022-2023 | |
| Lantheus Medical Imaging, INC. | $82.85 | 2023-2024 | Definity |
| E.R. Squibb & Sons, L.L.C. | $81.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.24 | 2022 | |
| Merck Sharp & Dohme LLC | $66.50 | 2022-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $49.00 | 2023 | |
| Impulse Dynamics (USA) INC. | $43.62 | 2022-2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $37.04 | 2022 | |
| Innovation Technologies INC | $29.84 | 2021 | |
| Medtronic Vascular, INC. | $27.01 | 2019-2020 | |
| Amgen INC. | $24.05 | 2023 | Repatha |
| Novo Nordisk INC | $20.90 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $17.77 | 2022 | |
| Boston Scientific Corporation | $15.30 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Najafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.